STRIDE combination in advanced liver cancer: a first-line look at tremelimumab plus durvalumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Italian multicenter observational study follows adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. Participants receive the STRIDE regimen and are followed to measure time to hepatic decompensation, quality of life, treatment effectiveness, and safety outcomes. The study does not randomize treatment and aims to describe real-world use of this first-line immunotherapy combination. Key eligibility includes Child-Pugh A status, ECOG 0–1, and BCLC B or C disease. Sites are located in Ancona and Bergamo, with AstraZeneca as lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \- Signed informed consent.
* Age ≥ 18 years.
* Histologically or radiologically confirmed diagnosis of advanced or unresectable HCC.
* BCLC B or C HCC.
* Child-Pugh A (score 5 or 6).
* Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1.
* Planned first-line treatment of advanced/uHCC with STRIDE.

Exclusion Criteria:

* \- Any previous line of systemic therapy for HCC.
* Any prior or concomitant immunotherapy.
* Prior allogeneic organ or bone marrow transplant.
* Documented active or previous GI bleeding within the previous 12 months.
* Main trunk portal vein thrombosis.
* Autoimmune disease requiring treatment with immunosuppressive medication.
* Known hypersensitivity to the active substance or to any of the STRIDE excipients.
* Pregnancy or breastfeeding

Where it's running

• Research Site
  Ancona, Italy Recruiting
• Research Site
  Bergamo, Italy Recruiting
• Research site
  Foggia, Italy Recruiting
• Research Site
  Foggia, Italy Recruiting
• Research Site
  Meldola, Italy Recruiting
• Research Site
  Milan, Italy Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: +1877240

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Durvalumab plus tremelimumab with or without liver-directed GEMOX chemotherapy for hepatocellular carcinoma

  This trial tests whether adding hepatic arterial infusion chemotherapy (GEMOX) to the immunotherapy combination durvalumab plus tremelimumab helps people with hepatocellular carcinoma who have a high tumor burden in the liver.

  Recruiting at 5 sites Phase 2/3 Unicancer · Bordeaux and 10 other locations · NCT06904170

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Biomarkers to predict outcomes in liver cancer treated with tremelimumab plus durvalumab

  This study will test whether blood biomarkers can predict how adults with unresectable or metastatic hepatocellular carcinoma respond to tremelimumab plus durvalumab (STRIDE regimen).

  Recruiting at 10 sites Centre Hospitalier Universitaire de Besancon · Besançon and 9 other locations · NCT06796114

• Combining Zanzalintinib with Immunotherapy for Liver Cancer

  This study is testing a new combination of a cancer drug and immunotherapy to see if it can help people with advanced liver cancer feel better and fight their disease.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania and 2 other locations · NCT06698250

• Treatment for advanced liver cancer with specific cirrhosis

  This study is testing a new combination treatment for advanced liver cancer in patients with specific cirrhosis to see if it can help them better than current options, especially focusing on those from underserved communities.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT06526104

• Triple treatment for advanced liver cancer patients

  This study is testing two different ways to treat advanced liver cancer to see which one works better for patients who can't have surgery.

  Recruiting at 3 sites Phase 2 Ludwig-Maximilians - University of Munich · Munich and 2 other locations · NCT05844046

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.